A Phase IIb, double blind randomized, controlled clinical trial, to evaluate the efficacy and safety of two Aramchol doses versus placebo in patients with Non-Alcoholic Steatohepatitis (NASH)
A study for patients with Non-Alcoholic Steatohepatitis (NASH using study drug armachol
Sponsor: Galmed
Enrolling: Male and Female Patients
IRB Number: AAAQ3206
U.S. Govt. ID: NCT02279524
Contact: Theresa Lukose: 212-305-6758 / tt2103@cumc.columbia.edu
Additional Study Information: This study is for patients with Nonalcoholic Steatohepatitis (NASH) and also suffer from obesity and Type 2 diabetes Mellitus type II or prediabetes. The purpose of this study is to determine the effect of Aramchol on liver inflammation, in addition to fat reduction in the liver. NASH (Nonalcoholic Steatohepatitis) is a common, often silent liver disease. The major characteristic of NASH is fat in the liver along with inflammation and damage. NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged. Currently there are no therapies approved for the treatment of NASH. Aramchol partially prevents an enzyme (protein produced by the body) from breaking down fatty acids and has the potential to be a disease modifying treatment for fatty liver disorders, including NASH.
This study is closed
Elizabeth Verna, MD
Do You Qualify?
Have you been diagnosed with Nonalcoholic Steatohepatitis (NASH)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Theresa Lukose